Cellectis SA

ALCLS

Company Profile

  • Business description

    Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

  • Contact

    8, rue de la Croix Jarry
    Paris75013
    FRA

    T: +33 181691600

    https://www.cellectis.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    222

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,826.6015.30-0.17%
CAC 407,696.2758.28-0.75%
DAX 4023,787.45146.68-0.61%
Dow JONES (US)44,828.53344.110.77%
FTSE 1008,822.910.29-0.00%
HKSE23,852.1363.93-0.27%
NASDAQ20,601.10207.971.02%
Nikkei 22539,582.00228.88-0.57%
NZX 50 Index12,764.951.65-0.01%
S&P 5006,279.3551.930.83%
S&P/ASX 2008,588.0015.00-0.17%
SSE Composite Index3,466.835.49-0.16%

Market Movers